- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03986658
Linear Asymmetric rTMS in Adolescent Treatment-Resistant Depression: Tolerability of Treatment Durations Ranging From Ten Days to One Day
Dose-Response Study of Linear Asymmetric rTMS in Adolescent Treatment-Resistant Depression: Tolerability of Treatment Durations Ranging From Ten Days to One Day
This is a pilot interventional study to investigate the acceptability, tolerability, and side effect profile for varying numbers of treatment sessions/day of a new rTMS treatment in adolescents with treatment-resistant depression (TRD). Conventional rTMS has been limited to sinusoidal biphasic electromagnetic pulses. In contrast, the First Dawn rTMS system by NeuroQore can sustain a repetitive linear asymmetric pulse. In addition, identification of rTMS treatment sites in adolescents with TRD most often relies on anatomic landmarks, but the First Dawn rTMS system utilizes personal fMRI data in a novel algorithm to determine where to apply the rTMS in each patient.
Based on adult data in healthy volunteers and patients with TRD, the investigators propose that the First Dawn rTMS system will be acceptable and well-tolerated by adolescents and will have minimal side effects. Please see https://clinicaltrials.gov/ct2/show/NCT02667041 for details on the completed pilot study in adults.
The investigators aim to investigate acceptability, tolerability, and side effects in groups of patients receiving treatment in numbers of sessions/day that are gradually accelerated over the course of the study. Results will be used to inform the development of a randomized controlled trial.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The 18 patients will be placed into 6 sub-groups sequentially as they are enrolled. All patients will receive a maximum of 30,000 pulses in their treatment course, as tolerated. The first group will receive daily sessions, similar to standard rTMS treatment. Each of the remaining groups will be set to receive more frequent sessions/day in decreasing numbers of days on a graduated schedule while holding the total number of pulses for each patient's treatment course at 30,000 pulses. in addition, the investigators will recruit one healthy volunteer to test fMRI server data transfer and analysis. This healthy volunteer will not receive rTMS.
Primary Objectives
The primary objectives of this study are to assess: 1) the feasibility of enrollment (number of patients who enroll divided by the number of patients approached), 2) study retention (number of patients completing the study divided by the number enrolled), and 3) AE/SE profile of the treatment at each protocol level and 4) patient experience in the study across the sample and within the sub-groups.
Secondary Objectives
The secondary objectives of this study are to: 1) evaluate daily changes in symptoms of depression and mental status; 2) evaluate fMRI changes in the LDLPFC after treatment; 3) evaluate post-treatment and 3-month changes in depression symptoms, global function, mental status, verbal memory.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Kathleen Pajer, MD
- Phone Number: 2723 613-737-7600
- Email: kpajer@cheo.on.ca
Study Contact Backup
- Name: Paula Cloutier
- Email: pcloutier@cheo.on.ca
Study Locations
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8L1
- Children's Hospital of Eastern Ontario
-
Contact:
- Kathleen Pajer, MD
- Phone Number: 2723 613-737-7600
- Email: kpajer@cheo.on.ca
-
Sub-Investigator:
- Robert Chen, MD, Toronto Western Hospital, University of Toronto
-
Sub-Investigator:
- Paula Cloutier, MA
-
Sub-Investigator:
- Addo Boafo, MD
-
Sub-Investigator:
- Elka Miller, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion:
- Meets criteria for DSM-5 MDD, as determined by a structured psychiatric interview.
Meets criteria for TRD:
- failed two adequate courses of antidepressant medication OR
- failed adequate course of medication AND one course of psychotherapy.
- Score of > 40 on Child Depression Rating Scale-Revised OR score of > 20 on Child Depression Inventory-2.
- Fluent in speaking and reading English.
Exclusion:
- Positive pregnancy test.
- Current or past: bipolar disorder, psychotic disorder, autism spectrum disorder, intellectual disability, substance use disorder, conduct disorder, as determined by a structured psychiatric interview.
- Medical illness that could lower the seizure threshold, e.g., epilepsy from any cause.
- Medications that could lower the seizure threshold or affect brain function.
- Psychotropic medications changed in two weeks prior to enrollment.
- Fails the TMS safety screening questionnaire.
- Fails fMRI screening process.
- Left-handed (may indicate different cortical lateralization which could affect outcomes).
- Involuntarily committed to the hospital.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Adolescents
Device: First Dawn rTMS System used in 18 patients divided into groups of 3.
Each group will receive a different and gradually increasing frequency of treatment sessions/day (1-10) over a decreasing number of days (10-1).
The total number of pulses for all levels will be 30,000.
The use of each level will be dependent on tolerability and safety of the previous lower level, i.e., if one level is not tolerated well by a group, progression to the next level will not occur.
|
Linear Asymmetric rTMS System
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Enrollment Rate
Time Frame: Through study completion, an average of 10 months
|
Number of patients who give consent divided by the number who are approached.
|
Through study completion, an average of 10 months
|
Patient Completion Rate
Time Frame: Through study completion, an average of 10 months
|
Number of patients who complete the study divided by the number of patients who enroll in the study.
|
Through study completion, an average of 10 months
|
Side Effects Profile
Time Frame: Through study completion, an average of 10 months
|
Measured with the rTMS Side Effect Questionnaire
|
Through study completion, an average of 10 months
|
Patient Experience
Time Frame: Through study completion, an average of 10 months
|
Measured with the Multi-Care Institute for Research and Innovation Research Participant Satisfaction Questionnaire
|
Through study completion, an average of 10 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in self-reported MDD symptoms
Time Frame: Change from baseline score to score at 3 months
|
Measured with the Child Depression Inventory-2.(CDI-2)
|
Change from baseline score to score at 3 months
|
Change in clinician-rated MDD symptoms
Time Frame: Change from baseline score to score at 3 months
|
Measured with the Child Depression Rating Scale-Revised (CDRS-R)
|
Change from baseline score to score at 3 months
|
Change in function
Time Frame: Change from baseline score to score at 3 months
|
Measured with the Children's Global Assessment Scale (C-GAS)
|
Change from baseline score to score at 3 months
|
Change in mental status
Time Frame: Change from baseline score to score at 3 months
|
Measured with the Mini-Mental State Examination (MMSE)
|
Change from baseline score to score at 3 months
|
Change in short-term verbal memory
Time Frame: Change from baseline score to score at 3 months
|
Measured with the Hopkins Verbal Learning Test-Revised (HLVT-R)
|
Change from baseline score to score at 3 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Kathleen Pajer, MD, Children's Hospital of Eastern Ontario (CHEO)
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHEO19P1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Treatment Resistant Depression
-
Changping LaboratoryBeijing HuiLongGuan HospitalRecruitingTreatment-Resistant DepressionChina
-
Central Institute of Mental Health, MannheimCharite University, Berlin, Germany; German Federal Ministry of Education and... and other collaboratorsActive, not recruitingTreatment-resistant DepressionGermany
-
Janssen Research & Development, LLCCompletedTreatment-resistant DepressionUnited States, Australia, France, United Kingdom, Belgium, Germany, Taiwan, Spain, Argentina, Mexico, Poland, Bulgaria, Malaysia, South Africa, Turkey, Finland, Korea, Republic of, Brazil, Austria, Sweden, Lithuania
-
Janssen Research & Development, LLCCompletedTreatment-resistant DepressionUnited States, France, Belgium, Mexico, Canada, Brazil, Estonia, Hungary, Slovakia
-
University of OttawaCanadian Institutes of Health Research (CIHR)Completed
-
GH Research Ireland LimitedRecruitingTreatment-resistant DepressionIreland, Czechia
-
First Affiliated Hospital of Zhejiang UniversityRecruitingTreatment-resistant DepressionChina
-
University Hospital FreiburgBoston Scientific CorporationRecruitingTreatment-resistant DepressionGermany, France
-
Janssen Research & Development, LLCCompletedTreatment-resistant DepressionUnited States, Poland, Germany, Spain, Czechia
-
Millennium Pharmaceuticals, Inc.WithdrawnTreatment-Resistant Depression
Clinical Trials on Linear Asymmetric rTMS System
-
Encore Medical, L.P.TerminatedFemoral Fracture | Osteoarthritis | Rheumatoid Arthritis | Avascular Necrosis | Correction of a Functional DeformityUnited States
-
University of WashingtonNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedDepression | Chronic Pain | FibromyalgiaUnited States
-
Samsung Medical CenterCompleted
-
Medical University of South CarolinaTerminatedNicotine Dependence | Nicotine Use DisorderUnited States
-
Stanford UniversityCornell University; Foundation for OCD ResearchRecruitingObsessive-Compulsive DisorderUnited States
-
New York State Psychiatric InstituteSuspended
-
Washington University School of MedicineCompleted
-
National Cheng-Kung University HospitalMinistry of Science and Technology, TaiwanUnknownTranscranial Magnetic Stimulation | Heroin DependenceTaiwan
-
Nanjing Medical UniversityThe First Affiliated Hospital with Nanjing Medical University; The Third Affiliated... and other collaboratorsCompletedAcute Respiratory Distress Syndrome
-
New York State Psychiatric InstituteNational Institute of Mental Health (NIMH); Global Foundation for Eating Disorders and other collaboratorsActive, not recruiting